ArticleAnnals of the Child Neurology Society2026
Non-Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature.
Article in Annals of the Child Neurology Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course. TDLs can cause severe presentations given their size, edema, and associated mass effect, making prompt diagnosis and effective treatment crucial. Patient Description: We present four adolescents with TDLs who tested negative for aquaporin-4-IgG and myelin oligodendrocyte glycoprotein (MOG)-IgG and did not meet diagnostic criteria for any known demyelinating disorder. All four patients underwent extensive and inconclusive workup for the etiology of their radiographic and clinical findings and received multiple immunomodulators with some clinical improvement, although three of the four had multiple relapses. Conclusions: TDLs that do not meet criteria for the known demyelinating syndromes can cause significant neurological sequelae. We describe four adolescents with neurological symptoms associated with TDLs. Given the rare but serious occurrence of these non-syndromic TDLs, more well-powered studies are critical to guide diagnosis, management, and response to therapies and eventually develop evidence-based protocols to manage other patients with similar presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.